Baxter's HDx remedy related to 25% decrease mortality fee for as much as 4 years – The Journal of Healthcare Contracting

Baxter's HDx remedy related to 25% decrease mortality fee for as much as 4 years – The Journal of Healthcare Contracting



Could 30, 2024 – Baxter Worldwide Inc. has introduced new information exhibiting that prolonged hemodialysis, often called HDx remedy, powered by Theranova dialyzer, was related to an roughly 25% decrease all-cause mortality threat for as much as 4 years in comparison with high-flux hemodialysis (HF HD). The research, “Survival of prolonged hemodialysis and high-flux hemodialysis sufferers in Colombia: a cohort research,” was introduced on the 61st Congress of the European Renal Affiliation-European Dialysis and Transplant Affiliation (ERA-EDTA) Congress, Could 23-26.

The brand new information comes from a 48-month observational cohort research of 1,092 dialysis sufferers at 11 Baxter Renal Care Companies Facilities in Colombia. Within the research, 533 sufferers obtained high-flux hemodialysis and had been in contrast with 559 sufferers who obtained HDx remedy.

HDx remedy focuses on the environment friendly removing of large-middle molecules, permitting filtration nearer to that of the native kidney. Many of those giant center molecule uremic toxins have been related to the event of irritation, heart problems, and different comorbidities in dialysis sufferers.

HDx remedy makes use of Baxter's Theranova dialyzer, geared up with the MCO membrane, which filters a wider vary of uremic toxins from the blood, particularly focusing on the big center molecules that aren’t successfully eliminated by standard hemodialysis therapies.

Be taught extra

Leave a Reply

Your email address will not be published. Required fields are marked *